All In Biotech

Drug Trial Radar · NCT06909825

FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

A Phase 2, Open-label, Multi-centre Study of FPI-2265 (225Ac-PSMA-I&T) and Olaparib in Participants With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

85

Planned (sponsor's estimate)

Start

Feb 26, 2025

Primary completion

May 2027

Study completion May 2027

Sponsor

Lead sponsor
Fusion Pharmaceuticals Inc.Industry
Sponsor type
Industry
First posted
Apr 4, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is an open-label, multicenter study designed to investigate the efficacy, safety and tolerability of FPI-2265 (225Ac-PSMA-I\&T) in combination with Olaparib in participants with mCRPC. The dose optimization Phase 2 part will be investigating the safety, tolerability, and anti-tumor activity of novel dosing regimens of FPI-2265 and Olaparib in participants with metastatic castration-resistant prostate cancer.

Conditions

  • Metastatic Castration-resistant Prostate Cancer

Interventions

  • FPI-2265Drug

    PSMA ligand radiolabeled with Ac225

  • OlaparibDrug

    Poly (ADP-ribose) polymerase (PARP) inhibitor

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluate anti-tumour activity of FPI-2265 administered in combination with olaparibTime frame: From first dose until approximately 12 weeks after the first administered dose of FPI-2265
  2. Evaluate the safety and tolerability of FPI-2265 administered in combination with olaparibTime frame: From first dose until end of long-term follow-up, 5 years from the last administered dose of FPI-2265

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Macquarie University Hospital

    Macquarie Park, New South Wales, Australia

  • Princess Alexandra Hospital

    Woolloongabba, Queensland, Australia

  • Icon Cancer Centre Kurralta Park

    Kurralta Park, South Australia, Australia

  • Peter MacCallum Cancer Center

    Melbourne, Victoria, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.